Alphamab Oncology, a listed biotech firm located in BioBAY, has signed a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek ("Nanolek") to advance the commercialization of Armocibart (research code: KN057), a bleeding prophylaxis therapy for hemophilia A and hemophilia B, in Russia, the Eurasian Economic Union (EAEU), Azerbaijan and Uzbekistan. The agreement was inked at the Eurasian Pharmaceutical Cooperation Forum held in Shanghai. Mr. Evgeny Barinov, CEO of Nanolek, and Mr. Xue Chuanxiao, Shareholder and Director of Suzhou Alphamab Oncology, jointly executed the document. Under the terms of the agreement, Nanolek will be granted exclusive rights to register, promote and commercially operate Armocibart within the agreed territories, and will serve as the Marketing Authorization Holder (MAH) for the product. Mr. Xue Chuanxiao commented: "Nanolek boasts extensive experience in introducing innovative medicines to Russia and broader Eurasian markets, and we are delighted to establish this partnership. We believe this collaboration will grant greater patient populations access to state-of-the-art prophylactic treatments for hemophilia." Armocibart is a subcutaneously administered therapy indicated for the prevention of bleeding episodes in patients with hemophilia A or hemophilia B, with or without inhibitors. Its subcutaneous delivery route offers greater convenience for patients compared with intravenous clotting factor infusion regimens. Hemophilia is a rare inherited disorder primarily characterized by impaired blood clotting, arising from mutations in the genes encoding clotting factor VIII or factor IX. Patients are typically diagnosed at around two years of age on average. Hemophilia with inhibitors is defined by the production of antibodies targeting clotting factor VIII (in hemophilia A) or factor IX (in hemophilia B) within the patient’s body. These antibodies neutralize the corresponding clotting factors, diminishing the efficacy of replacement therapy and rendering conventional hemophilia treatments ineffective. For Russia, the clinical launch of a tissue factor pathway inhibitor (TFPI) inhibitor will deliver a first-in-class global prophylactic therapy against bleeding for patients living with hemophilia A and B, whether they have clotting factor inhibitors or not. Mr. Evgeniy Barinov added: "Per Russia’s patient registry data, more than 8,500 patients living with hemophilia A and B are currently registered nationwide. Standardized long-term treatment is critical for most of these patients to preserve quality of life and avert severe complications. We view this collaboration with Suzhou Alphamab Oncology as a key initiative to expand our orphan drug portfolio and improve Russian patients’ access to cutting-edge biotherapies."

Harbour BioMed (HKEX: 02142.HK), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, and BioMap, a global leader in AI foundation models for life sciences, today jointly announced a multi-dimensional, long-term strategic partnership centered on AI-driven discovery and development of complex biologics. The alliance aims to systematically overcome the critical bottlenecks constraining next-generation innovative therapies and to build a globally competitive, AI-powered R&D ecosystem. Under the strategic collaboration framework, the two companies will jointly launch MegaStream TechBio, a next-generation AI-native pipeline company targeting global markets. MegaStream will integrate a proprietary ecosystem of exclusive datasets × purpose-built large models × large-scale innovative pipeline portfolio into an AI-powered R&D engine. This engine is enabled by an advanced integrated intelligent dry–wet closed loop discovery laboratory, paired with a partner-tailored, multimodal and multi-objective generative large model. Focused on addressing critical unmet clinical needs across cardiovascular, renal, oncology and anti-aging areas, MegaStream prioritizes First-in-Class (FIC) and Best-in-Class (BIC) assets as its core development benchmarks. The company will systematically advance a broad portfolio of differentiated complex biologics into clinical-stage development at scale, aiming to emerge as the world’s leading AI-native complex biologics company. As the lead founding partner, Harbour BioMed will grant access to MegaStream with its unique fully human antibody platform, in-depth target biology know-how, and global clinical development capabilities. BioMap, as co-founding partner, will contribute foundational AI technology, model engineering, and intelligent R&D capabilities to accelerate pipeline development. MegaStream's initial pipeline will consist of AI-identified drug candidates from the parties’ earlier collaborations, as well as newly launched AI-driven discovery programs. The founding parties will be entitled to potential upfront payments, success-based milestones, and royalty sharing in accordance with industry practice. In addition, MegaStream’s core management team will be composed of seasoned executives from multinational biopharmaceutical companies and leading experts in artificial intelligence, with key appointments currently underway. As Co-founding Partners of MegaStream, Harbour BioMed and BioMap will jointly advance three core strategic pillars: I. Build a World-Leading Proprietary AIDD Infrastructure Platform — Defining the Next-Generation Engineering Paradigm for Complex Biologics Harbour BioMed and BioMap will build a globally leading AI-driven complex biologics AIDD infrastructure platform for MegaStream, powered by BioMap's premier life science foundation models, xTrimo, and the massive, high-quality datasets generated by Harbour BioMed's proprietary Harbour Mice® fully human antibody platform. This strategic alliance sees BioMap leverage its life science foundation models alongside Harbour BioMed’s high-quality full datasets. Performing systematic training, optimization and iteration tailored to the unique traits of complex biologics — which differ markedly from standard proteins and antibodies — the two sides have built a dedicated, self-evolving MegaStream large model. As the company’s AI backbone, this model will be deeply optimized for next-generation complex biologic modalities—including multispecific antibodies, XDC conjugates, in vivo CAR-T, and inhaled/oral biologics—delivering robust performance advantages and enabling end-to-end AI-driven design, from sequence generation to developability optimization. II. Build a Next-Generation Integrated Dry-wet Closed Loop Discovery Laboratory — Enabling Efficient Validation and Continuous Data Accumulation for AI-Native Molecules Leveraging the MegaStream large model, the two companies will integrate Harbour BioMed's extensive proprietary experimental capabilities with BioMap's expertise in automated discovery orchestration, high-throughput data analysis, and model iteration—delivered through the BioMap OS discovery platform—to construct a next-generation intelligent high-throughput dry–wet discovery laboratory. Tailored to the training and validation of multi-objective biological parameter models for complex biologics, as well as ongoing data accumulation and model iteration across the drug R&D lifecycle, the laboratory will establish a world-leading intelligent control hub and integrated experimental capabilities. It will achieve four core breakthroughs: fully intelligent orchestration, high-performance experimental validation, comprehensive automated data capture and analysis, and highly efficient AI modeling and model evolution—forming a complete Design-Build-Test-Learn (DBTL) automated closed loop. Once operational, this AI-native laboratory is projected to deliver greater than 500% efficiency gains over previous-generation platforms, dramatically accelerating complex biologics discovery and iteration. Data accumulation efficiency will increase by more than 10-fold, with the system expected to generate over 5 petabytes of high-quality, AI-ready life science data within five years—continuously fueling rapid AI model evolution. III. Scale Up Next-Generation R&D Pipelines: End-to-End Loop from AI Creation to Clinical Value Harbour BioMed and BioMap's first AI+ biotech-driven FIC pipeline collaboration dates back to 2021, encompassing property prediction, optimization, and generative design across more than 10 pipeline programs. Powered by the newly established AI complex biologics platform, FIC/BIC discovery capabilities will be substantially enhanced—enabling Harbour BioMed and MegaStream to advance hundreds of innovative programs in parallel. By replacing traditional repetitive screening with AI model predictions and targeted, high-precision validation, and leveraging the power of generative AI models, the platform will produce pipeline molecules with superior performance metrics, more comprehensive multi-objective optimization, and more precise programmable control. In the coming years, the two companies will accelerate the clinical translation of both existing assets and newly initiated FIC/BIC programs—building an industry-leading, fully integrated value chain from AI-powered discovery to clinical realization. Dr. Jingsong Wang, Founder, Chairman, and Chief Executive Officer of Harbour BioMed and Chairman of MegaStream TechBio, said: "This partnership opens a new chapter in biopharmaceutical innovation. We bring over a decade of world-class, proprietary antibody data from our Harbour Mice® platform. BioMap brings a 268-billion-parameter life science AI engine. Together, we are closing the loop from AI molecular design to clinical development—systematically raising the speed and success rate of next-generation complex biologics discovery. MegaStream will complete its corporate setup and launch its first pipeline portfolios with proven execution efficiency. We also look forward to joining hands with long-term global partners and top-tier investors to unlock new opportunities across the industry." Mr. Wei Liu, Co-Founder and Chief Executive Officer of BioMap, said: "BioMap was built to push AI to the frontier of biology—to give drug developers a platform capable of running generative, multi-objective discovery at scale. Harbour BioMed's Harbour Mice® and Hu-mAtrIx™ platforms are the gold standard in data-rich antibody engineering. By integrating their unique data assets and deep drug development expertise with our xTrimo foundation models, we are building something the industry has never seen: a true generative AI infrastructure for biopharma. This sets a new paradigm for how AI can power drug discovery across the entire field." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUSTM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIxTM AI platform, accelerating the development of innovative therapies. By integrating Harbour Mice®, HBICE®, HCAb PLUSTM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com. About BioMap BioMap is a global leader in AI foundation models for life sciences, dedicated to building next-generation AI infrastructure to accelerate scientific discovery across the industry. Our proprietary 268-billion-parameter life sciences foundation model family, xTrimo, learns the underlying rules governing genes, proteins, cells, and biological systems, delivering highly accurate AI-driven predictions. It has achieved state-of-the-art (SOTA) performance across more than 300 predictive tasks spanning over 20 life science subfields, and was awarded the championship title at the first global Virtual Cell Challenge. Built upon our foundation model, our product BioMap OS is an AI-powered life sciences discovery system that enables users to establish systematic AI capabilities. Through AI-driven dry–wet closed-loop discovery, it supports data insights, parameter optimization, and de novo design, while empowering users to accumulate proprietary data and train their own AI models, continuously enhancing their AI capabilities over time. BioMap currently supports over 800 institutional users worldwide, spanning multiple verticals including antibody and protein, innovative therapies and precision medicine, synthetic biology, and frontier scientific research. For more information, please visit .

According to the National Medical Products Administration’s Drug Clinical Trial Registration and Information Publicity Platform, ABO1108, a lyophilized mRNA shingles vaccine independently developed by BioBAY-based enterprise Abogen Biosciences, has been formally registered to launch its Phase III clinical trial. This marks the world’s first mRNA vaccine against herpes zoster to enter Phase III research, placing China once again at the global forefront of mRNA vaccine technology. Founded in 2019, Abogen Biosciences is one of China’s earliest biotech firms dedicated to messenger ribonucleic acid (mRNA) therapeutics research and development. Established by Dr. Ying Bo, the company owns an industry-leading mRNA and lipid nanoparticle (LNP) delivery platform with fully independent intellectual property rights. It is among the few domestic enterprises boasting full-value-chain capabilities for mRNA drug development, covering mRNA design, formulation development and large-scale manufacturing. Since its founding, Abogen has built a diversified product pipeline spanning infectious disease prevention and tumor immunotherapy. Its core platform component—ionizable lipid—is the sole domestically developed LNP ingredient validated in large-scale Phase III trials with proprietary intellectual property, and has obtained patent approvals in China, the United States, Australia and multiple major European countries. ABO1108 has achieved an exceptionally fast clinical development timeline. On March 28, 2025, its Investigational New Drug (IND) application received implied clinical approval from the NMPA. On May 15 the same year, its Phase I trial kicked off in Rongshui, Guangxi, making it one of China’s first lyophilized mRNA shingles vaccines to enter human studies. The Phase I trial enrolled 180 healthy adults aged 40 years and above to evaluate the vaccine’s tolerability, reactogenicity and safety. The Phase II trial followed closely, with public registration published on November 10, 2025, targeting 300 participants. Its primary endpoint assessed immunogenicity within 30 days post-vaccination, including geometric mean concentration of anti-gE antibodies and VZV-specific T-cell responses. Volunteer recruitment for ABO1108’s Phase III study officially launched between March and April 2026, after securing ethical approvals from the NMPA and provincial CDC ethics committees. This Phase III trial plans to enroll 18,000 subjects, led by Director Huang Teng from the Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, and will be conducted simultaneously at CDCs across four provinces: Guangxi, Zhejiang, Hebei and Shandong. The vaccination regimen mirrors existing recombinant shingles vaccines, consisting of two doses administered 60 days apart. Herpes zoster (shingles) is an infectious skin disease triggered by reactivation of the varicella-zoster virus (VZV), predominantly affecting people over 40 and patients with chronic illnesses. Its hallmark symptoms include clustered blisters accompanied by severe neuralgia. Post-herpetic neuralgia may persist for months or even decades, severely impairing patients’ quality of life. Data from the Chinese Expert Consensus on Diagnosis and Treatment of Herpes Zoster (2023 Edition)shows the annual incidence among Chinese adults aged over 50 stands at 3.94–5.8 per 1,000 person-years, with incidence doubling every decade after age 50. Globally, GSK’s Shingrix recorded sales exceeding £3.558 billion (approximately USD 4.705 billion) in 2025, ranking among the world’s top three highest-revenue vaccines for five consecutive years, which underscores the enormous market potential for shingles prophylaxis. A standout technical differentiator of ABO1108 is its lyophilized formulation. Conventional mRNA vaccines demand ultra-cold cold-chain storage at -20°C to -70°C, creating substantial logistical barriers for distribution and grassroots rollout. Leveraging lyophilization technology, ABO1108 delivers drastically enhanced thermal stability, enabling long-term storage under standard 2–8°C refrigeration. This innovation slashes transportation and warehousing costs and greatly improves vaccine accessibility, particularly for remote regions and primary healthcare facilities. As the only mRNA shingles vaccine publicly disclosed to have progressed to Phase III clinical trials worldwide, ABO1108 holds a global leadership position in development speed. The milestone strongly validates China’s indigenous mRNA vaccine research and manufacturing capacity. As a national biomedical industry hub, BioBAY will continue to support and advance such breakthrough programs, offering an entirely new Chinese solution for global shingles prevention.

Innovent Biologics, a listed biotech enterprise based in BioBAY, and Pfizer jointly announced the signing of a global strategic cooperation agreement covering 12 early-stage and first-in-class oncology R&D programs with groundbreaking therapeutic potential. The deal encompasses multiple collaboration frameworks including licensing, co-development and co-commercialization (Co-Co). The asset portfolio features a series of antibody-drug conjugates (ADCs) equipped with novel differentiated payloads, as well as multispecific antibodies boasting distinctive immunomodulatory profiles and proprietary structural designs. Under the agreement, Innovent Biologics will receive an upfront payment of USD 650 million, plus eligibility for up to USD 9.85 billion in research, regulatory and commercial milestone payments, bringing the total aggregate transaction value to USD 10.5 billion. Additionally, Innovent is entitled to double-digit tiered royalties on net sales for each successfully approved asset. For programs under the co-development and co-commercialization model, profits generated in the U.S. and Europe will be split equally between the two parties. This strategic alliance integrates Innovent’s strengths in oncology target discovery and early clinical development with Pfizer’s deep expertise spanning global research, multinational clinical execution, regulatory affairs and large-scale commercialization. The two companies deliver strong complementary capabilities in core therapeutic areas to drive synergistic innovation. The collaboration covers an oncology portfolio of 12 programs: eight early-stage assets originating from Innovent’s pipeline and four brand-new de novo programs to be proposed by Pfizer. As individual assets advance through successive clinical phases, select programs will enter joint co-development, with associated development costs shared by both partners. Dr. Zhou Hui, Chief R&D Officer (Oncology Pipeline), Innovent Biologics “This strategic partnership unites the world-class expertise of Innovent and Pfizer in oncology, accelerating global access to transformative cancer therapies for more patients worldwide. By fully leveraging our complementary resources and capabilities, we can advance Innovent’s early oncology pipeline at an accelerated pace with broader global reach, delivering breakthrough treatments to patients around the globe more efficiently. Furthermore, global co-development and joint commercialization in the U.S. and Europe for core assets will further expand Innovent’s international footprint. Innovent continues to strengthen its globalized oncology R&D platform, committed to delivering treatment options that deliver lasting, far-reaching value to patients worldwide.” Jeff Legos, Chief Oncology Officer, Pfizer “Patients stand at the center of every R&D initiative and collaboration at Pfizer, and we maintain a sense of urgency to continuously redefine treatment possibilities for people living with cancer. This partnership brings together two highly complementary innovation powerhouses aligned around a shared mission: to deliver truly transformative novel medicines to global patients faster and more efficiently. By combining Innovent’s prowess in novel drug discovery and early clinical development with Pfizer’s end-to-end global R&D and commercialization infrastructure, we stand to not only enrich our pipeline but also expedite the arrival of paradigm-shifting therapies that reset standards of care and create meaningful, lasting improvements in patients’ lives.” Per the terms of the agreement, Innovent will leverage its proprietary discovery platform and robust early clinical development capabilities to advance partnered assets through Phase I trials, after which Pfizer will take the lead on subsequent clinical development. Detailed licensing and commercialization terms are outlined below: Four key programs will be co-developed globally with shared development costs. The two parties will co-commercialize these assets and split profits in the U.S. and Europe*, while Innovent retains all rights for Greater China; Exclusive rights to four programs outside Greater China are licensed to Pfizer, who will bear the majority of related development costs; Global exclusive licensing rights for another four programs are granted to Pfizer, who will cover all worldwide development expenses. The transaction is expected to close following receipt of all required regulatory clearances. *“Europe” refers to all European Union member states and the United Kingdom.